Navigation Links
Shire plc: Long Term Incentive Plan

BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, March 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announces the release on March 25, 2008, of ordinary shares of 5 pence in the capital of Shire plc ("Shares") in connection with the Shire Long Term Incentive Plan ("LTIP").

In accordance with the rules of the LTIP, the following Shares were released:

Name of PDMR Number of Shares


Mr M Emmens 75,408

Mr A Russell 46,634

Ms T May 30,746

Mr J Rus 23,365

Ms A Graham 18,843

The LTIP awards were subject to performance criteria and, in accordance with the rules of the LTIP, the number of Shares to be released was approved by the Remuneration Committee in 2007. Whilst the performance period is measured over three years, the Shares are only released after the fourth anniversary of the grant. The LTIP awards were satisfied by way of a cash payment, being a sum equal to the cash equivalent of the number of Shares released. The cash equivalent was determined by using the middle market quotation of the Shares on the business day preceding the day on which entitlement arose.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
T May

Company Secretary

Notes to editors

Shire plc Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the Specialist physician. Shire focuses its business on attention deficit and Hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shire plc: IFRS Results for the Year Ending December 31, 2007
2. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
3. Shire plc: Correction Re Website
4. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
5. Shire Engages Palio
6. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
7. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
10. Shire plc: Board Changes
11. David Mott Appointed Non Executive Director at Shire
Post Your Comments:
(Date:11/26/2015)... England , November 26, 2015 ... an innovative medical device company specializing in imaging technologies, announced ... the European Commission as part of the Horizon 2020 European ... to carry out a large-scale clinical trial in breast cancer. ...      (Logo: , --> ...
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
Breaking Biology News(10 mins):